Poolbeg Pharma PLC RSV AI Drug Candidate Analysis Update (3715X)
20 Diciembre 2023 - 1:00AM
UK Regulatory
TIDMPOLB
RNS Number : 3715X
Poolbeg Pharma PLC
20 December 2023
Poolbeg Pharma plc
Positive Outputs from Lab-Based Analysis of RSV Drug Candidates
Identified Using AI
RSV drug candidates with the highest probability of success
prioritised
20 December 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF,
'Poolbeg' or the 'Company'), a biopharmaceutical company focussed
on the development and commercialisation of innovative medicines
targeting diseases with a high unmet medical need, announces the
positive outputs from the lab-based analysis and successful
prioritisation of the Respiratory Syncytial Virus ('RSV') drug
targets and treatments identified as part of its artificial
intelligence ('AI') led programme.
Poolbeg's team of scientific experts have reviewed the
comprehensive data package obtained from this lab-based analysis
and has strategically prioritised a select number of the RSV drug
candidates that were analysed. The Company is actively exploring
the most effective way to progress the prioritised drug candidates
in order to generate value. Poolbeg believes the data obtained
reflects the high potential of this AI-led programme and supports
its partnering efforts.
The global interest in AI-led drug discovery continues to grow,
with major pharmaceutical players making substantial investments in
the field. Poolbeg's RSV AI programme identified these drug
treatment candidates in just 10 months. AI-led drug discovery can
accelerate the timeline achievable which reduces costs while also
decreasing risks and providing a higher likelihood of success in
bringing groundbreaking therapies to patients.
Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg
Pharma, commented: "The positive outputs from this analysis, and
the successful prioritisation of our RSV drug candidates, is a
testament to the power of our AI-led drug discovery programme. As
we engage in partnering discussions, these results position Poolbeg
as a key player in the evolving landscape of AI-driven drug
discovery."
- Ends -
Enquiries
Poolbeg Pharma Plc
Jeremy Skillington, CEO
Ian O'Connell, CFO +44 (0) 207 183 1499
Cavendish Capital Markets Ltd (Nominated
Adviser & Joint Broker)
Geoff Nash, Charlie Beeson, Nigel
Birks, Harriet Ward (ECM) +44 (0) 207 220 0500
Singer Capital Markets (Joint Broker)
Phil Davies, Sam Butcher +44 (0) 207 496 3000
J&E Davy (Joint Broker)
Anthony Farrell, Niall Gilchrist +353 (0) 1 679 6363
Optimum Strategic Communications +44 (0) 208 078 4357
Nick Bastin, Vici Rabbetts, Elena poolbeg@optimumcomms.com
Bates
About Poolbeg Pharma
Poolbeg Pharma plc is committed to the development and
commercialisation of innovative medicines targeting diseases with a
high unmet medical need. Its model focusses upon developing its
exciting clinical assets and commercialising approved and marketed
drugs to fund the development of its robust pipeline of innovative
products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history
of delivering significant shareholder value. The team has been
strengthened by the appointment of three former members of the
Amryt Pharma plc leadership team, with the intention of repeating
Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets
including CRS induced by cancer immunotherapies, infectious
disease, and metabolic conditions such as obesity with the
development of an oral GLP-1R agonist. It uses a cost-effective
development philosophy to generate high quality human data to
support partnering and further development. Its AI-led infectious
disease programmes analyse unique data from human challenge trials
to identify clinically relevant drug targets and treatments,
leading to faster development and greater commercial appeal.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
About RSV
Respiratory Syncytial Virus (RSV) which inflames the smallest
airways of the lungs, sends an average of 58,000-80,000 children
under the age of five to hospital each year in the US alone,
according to the US Centers for Disease Control and Prevention
(CDC). RSV can also be dangerous for adults over the age of 65,
resulting in around 177,000 hospitalisations per year in the United
States alone.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDBRBDDLSBDGXC
(END) Dow Jones Newswires
December 20, 2023 02:00 ET (07:00 GMT)
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Poolbeg Pharma (LSE:POLB)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024